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Summary
 
The movement of leukocytes into tissues is regulated by the local production of chemical me-
diators collectively referred to as chemoattractants. Although chemoattractants constitute a di-
verse array of molecules, including proteins, peptides, and lipids, they all appear to signal leu-
kocytes through a related family of seven transmembrane–spanning G protein–coupled
receptors. The eosinophil is a potent proinflammatory cell that is attracted into tissues during
allergic inflammation, parasitic infection, and certain malignancies. Since the molecular mecha-
nisms controlling eosinophil recruitment are incompletely understood, we performed a degen-
erate polymerase chain reaction on cDNA isolated from murine eosinophils to identify novel
chemoattractant receptors. We report the isolation of a cDNA that encodes a 351–amino acid
glycoprotein that is 78% identical to a human gene that has been reported to be a purinoceptor
(P2Y
 
7
 
) and a leukotriene B
 
4
 
 (LTB
 
4
 
) receptor (BLTR). Chinese hamster ovary (CHO) cells
transfected with this cDNA specifically bound [
 
3
 
H]LTB
 
4
 
 with a dissociation constant of 0.6 
 
6
 
0.1 nM. Furthermore, LTB
 
4
 
 induced a dose-dependent intracellular calcium flux in transfected
CHO cells. In contrast, [
 
35
 
S]dATP did not specifically bind to these transfectants. This mRNA
was expressed at high levels in interleukin 5–exposed eosinophils, elicited peritoneal macro-
phages and neutrophils, and to a lesser extent interferon 
 
g
 
 stimulated macrophages. Low levels
of expression were detected in the lung, lymph node, and spleen of unchallenged mice. West-
ern blot analysis detected the mBLTR protein in murine eosinophils and alveolar macrophages
as well as human eosinophils. In addition, elevated levels of mBLTR mRNA were found in
the lungs of mice in a murine model of allergic pulmonary inflammation in a time course con-
sistent with the influx of eosinophils. Our findings indicate that this murine receptor is an LTB
 
4
 
receptor that is highly expressed on activated leukocytes, including eosinophils, and may play
an important role in mediating eosinophil recruitment into inflammatory foci.
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T
 
he attraction of leukocytes from the blood into the tis-
sue is a critical component of the host inflammatory
response. The eosinophil is a blood-borne leukocyte that is
thought to play an important role in host defense against
helminthic parasites by exocytosing its cytotoxic granular
constituents, such as eosinophil major basic protein and
eosinophil peroxidase, in the vicinity of the pathogen (1).
However, these cytotoxic proteins are also harmful to host
tissue and contribute to the tissue destruction seen in a va-
riety of diseases where eosinophils accumulate, such as
asthma and other allergic diseases (2). The regulation of
eosinophil recruitment into the tissue is a complex process
that is not completely understood but involves adhesion
molecules, such as vascular cell adhesion molecule 1, very
late activation antigen 4, and chemoattractants (3–5).
A number of eosinophil chemoattractants have been
identified, including the proteolytic fragment of comple-
ment, C5a, the formylated peptide met-leu-phe (FMLP),
 
1
 
1
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numerous chemokines, and several lipid mediators (4, 6).
The chemokines are a large superfamily of 8–10-kD se-
creted proteins that play a role in controlling the move-
ment of leukocytes (7, 8). Several chemokines, including
eotaxin-1 and -2, RANTES (regulated on activation, nor-
mal T cell expressed and secreted), macrophage inflamma-
tory protein (MIP)-1
 
a
 
, and monocyte chemoattractant
protein (MCP)-2, -3, and -4, chemoattract unstimulated
peripheral blood eosinophils isolated from nonatopic do-
nors, whereas IL-8 is active on activated eosinophils (5,
9–13). The lipid mediator platelet-activating factor (PAF) is a
potent chemoattractant for purified human and mouse eo-
sinophils, whereas the metabolite of arachidonic acid, leu-
kotriene B
 
4
 
 (LTB
 
4
 
), is a potent chemoattractant for purified
guinea pig eosinophils with relatively little activity on un-
stimulated human eosinophils (14–18).
Chemoattractants direct the movement of leukocytes by
signaling cells through specific surface receptors. The chemoat-
tractant receptors constitute a subfamily of the G protein–
coupled seven transmembrane–spanning family of receptors
(STR) whose members are related in structure and func-
tion and include the receptors for C5a (19), PAF (20),
FMLP (21), lipoxin A
 
4 
 
(22), and the chemokine receptors
(7, 23). Several of these receptors have been shown to be
expressed in eosinophils, including the C5a receptor (C5aR;
references 24, 25) and the chemokine receptors CCR3,
CCR1, and CXCR2 (26–28). We were interested in isolating
novel eosinophil chemoattractant receptors and used de-
generate PCR on mouse eosinophil cDNA to isolate a cDNA
that is highly expressed in these eosinophils. This gene en-
codes a 351–amino acid glycoprotein that is 78% identical
to a human gene that has been reported to be a purinocep-
tor (P2Y
 
7
 
; reference 29) and an LTB
 
4 
 
receptor (BLTR; ref-
erence 30). We present data demonstrating that this murine
gene encodes a functional receptor for LTB
 
4
 
, and in con-
cordance with the human designation (30) and the consen-
sus nomenclature (31), we have proposed the name murine
(m) BLTR. Furthermore, we show that mBLTR is highly
expressed on eosinophils and in the lungs of mice after al-
lergic inflammation, suggesting that this receptor is impor-
tant for trafficking eosinophil into tissue.
 
Materials and Methods
 
Purification of Mouse Leukocytes.
 
Murine eosinophils were iso-
lated from the spleens of the CD2 promoter IL-5 transgenic mice
(32) by negative selection with anti–Thy-1 (M5/49), anti-B220
(6B2), anti–Lyt-2 (53-6.7), goat anti–rat serum-coated magnetic
beads, and a MACS magnet (Miltenyi Biotech, Auburn, CA; ref-
erence 33). The resulting eosinophil purity was 
 
.
 
90% as deter-
mined by microscopic examination of Diff-Quik–stained (Baxter
Scientific, McGaw Park, IL) cytocentrifuge preparations; con-
taminating cells were mononuclear. Peritoneal cells were har-
vested from healthy mice by peritoneal lavage. Intraperitoneal in-
jections of 9% sodium casein were used to elicit activated cells
into the peritoneal cavity. Elicited cells were collected by perito-
neal lavage and macrophages and neutrophils purified by Percoll
gradients (34). The cellular composition of each fraction was de-
termined by Diff-Quik–stained cytocentrifuge preparations. Bone
marrow cells were harvested from the femurs of pathogen-free
FVB female mice and were maintained in RPMI with either 30%
L cell–conditioned medium (source of M-CSF) and 20% FBS for
2 wk to obtain macrophages or 50% WEHI conditioned medium
(source of IL-3) and 10% FBS for 4 wk to obtain mast cells.
 
Isolation of a Novel mSTR cDNA.
 
Purified murine eosinophil
poly(A)
 
1
 
 RNA was used as a template to generate oligo dT
primed first strand cDNA (cDNA synthesis kit; Boehringer Mann-
heim Corp., Indianapolis, IN). Degenerate oligomers were syn-
thesized based on the well-conserved transmembrane domains
(TM) of chemoattractant G protein–coupled STRs: 5
 
9
 
 TM II tac
(c/a)(t/g)gctg(a/c)acctg(t/g)c(c/a)(t/g)tggccgac, 5
 
9
 
 TM III gaccg
(t/c)tacctggccat(t/c)gtcca(t/c)gccac, 3
 
9
 
 TM III gtgc(a/g)tggac(a/g)-
atggccaggta(a/g)cggtc, 3
 
9
 
 TM VII (g/a)taga(t/g)ga(t/g)ggggtt(g/c)-
ag(g/a)ca(g/a)c(t/a). PCR was performed using 100 pmol of the
oligomer pairs 5
 
9
 
 TM II and 3
 
9
 
 TM III, 5
 
9
 
 TM II and 3
 
9
 
 TM
VIII, 5
 
9
 
 TM III and 3
 
9
 
 TM VIII, 1 
 
m
 
l murine eosinophil first stand
cDNA, and 0.5 U Taq polymerase (Perkin Elmer, Foster City,
CA) in 75 
 
m
 
l with an initial 5 cycles of annealing at 37
 
8
 
C for 60 s,
followed by 25 cycles at 50
 
8
 
C for 60 s (denaturation at 95
 
8
 
C for
30 s and extension at 72
 
8
 
C for 90 s). PCR products were ligated
into TA cloning vector (Invitrogen Corp., Carlsbad, CA) and se-
quenced. Several clones from the PCR reaction using the TM II
and TM III primers designated C1.2, C1.4, and C1.5 contained
an identical, novel 
 
z
 
200-bp insert with sequence homology to
the STRs. A murine eosinophil cDNA library was prepared using
the ZAP express cDNA library kit in the pBK-CMV phagemid
vector (Stratagene, La Jolla, CA) that contained 1.75 
 
3
 
 10
 
6
 
 inde-
pendent clones (98% recombinants). 10
 
6
 
 clones were screened in
duplicate with a 
 
32
 
P-Klenow–labeled 200-bp C1.4 insert under
conditions of high stringency (50% formamide, 10% dextran sul-
fate, 5
 
3
 
 SSC, 1
 
3
 
 Denhardt’s solution, 1% SDS, 100 
 
m
 
g/ml de-
natured herring sperm DNA, and 20 mM Tris at 42
 
8
 
C) and
washed at 65
 
8
 
C in 0.1
 
3
 
 SSC and 0.1% SDS for 40 min. 92 posi-
tive plaques were clearly identified in duplicate and 20 randomly
picked for analysis. Sequence analysis revealed that these clones
were from the same gene but had variable 5
 
9
 
 ends. One clone,
p65b, which represented a class of clones that contained an open
reading frame beginning with methionine, had the longest 5
 
9
 
 un-
translated region and contained a 3
 
9
 
 poly A tract. Therefore, this
clone was selected for further studies.
 
5
 
9
 
 Rapid Amplification of cDNA Ends.
 
The 5
 
9
 
 end of the mu-
rine p65b gene was isolated using two nested internal 5
 
9
 
 oligo-
mers tagaacaatgggcaacagagacaggg and agaaggtgctgcaggagatgtagt
and the 5
 
9
 
 Amplifinder 5
 
9
 
 Rapid Amplification of cDNA Ends
(RACE) Kit (CLONTECH Laboratories, Inc., Palo Alto, CA).
The RACE products were cloned and sequenced.
 
Northern Analysis.
 
RNA was isolated from the organs of nor-
mal FVB mice or from fresh lymphomas by lysing the tissue in
guanidinium isothiocyanate using a polytron and pelleting the
RNA through a 5.7 M CsCl
 
2
 
 cushion. The poly(A)
 
1
 
 fraction was
isolated from total RNA by oligo dT cellulose chromatography
(Pharmacia Biotech, Inc., Piscataway, NJ). Spontaneously arising
lymphomas were obtained from bigenic mice containing a c-myc
transgene and p53 null alleles (35). Histologically, these tumors
were comprised of nonadherent cells with a high mitotic rate,
containing large pleomorphic nuclei, multiple nucleoli, and
scanty cytoplasm, and were not infiltrated by normal leukocytes
(35). These tumors were Thy-1 positive by Northern blot and
described in Elson et al. (35). RNA STAT-60 (Tel-Test “B”,
Inc., Friendswood, TX) was used to isolate RNA from mouse
leukocytes and cell lines. RNA was fractionated on a 1.2% aga-
rose gel containing 0.7% formaldehyde, transferred to GeneScreen 
1065
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(Dupont-NEN, Boston, MA) overnight using 10
 
3
 
 SSC and hy-
bridized with a 
 
32
 
P-dCTP Klenow-labeled random primed p65b
cDNA probe and the ribosomal protein (rp) L32 (36) or a 28s
RNA probe (37) as a control of RNA loading. RNA was fixed to
membrane by first UV cross-linking (Stratalinker; Stratagene, La
Jolla, CA). The membranes were hybridized and washed under
conditions of high stringency described above.
 
In Vitro Translation.
 
Transcription of the p65b cDNA plas-
mid linearized with Xba1 was performed using T3 polymerase to
produce a sense cRNA (38). Transcription of the p65b cDNA
plasmid linearized with BamH1 was performed using T7 poly-
merase to produce an antisense cRNA. The cRNA was in vitro
translated in the presence of [
 
35
 
S]methionine (Dupont-NEN) us-
ing a rabbit reticulocyte lysate (Promega Corp., Madison, WI).
Translation was performed in the presence or absence of canine
pancreatic microsomal membranes. 5 
 
m
 
l of each translation reac-
tion was analyzed by 4–20% gradient Laemmli SDS-PAGE,
treated with Autofluor (National Diagnostics, Atlanta, GA) and
exposed to autoradiography.
 
Cell Culture and Transfection.
 
Chinese hamster ovary (CHO)
cells were grown in F-12/HAM medium supplemented with
10% FCS, 2 mM glutamine, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin (Mediatech, Herndon, VA) at 37
 
8
 
C and 5% CO
 
2
 
.
CHO cells were transiently transfected with 10 
 
m
 
g of the p65b
cDNA plasmid (which is in the pBK-CMV vector) per 10-cm
dish using Lipofectamine (GIBCO BRL, Gaithersburg, MD) and
cultured for 72 h before analysis. Mock transfected cells were
treated identically without the addition of DNA. CHO cells were
stably transfected with 15 
 
m
 
g of the p65b cDNA plasmid linear-
ized with Ssp1 in a 10-cm dish by the calcium phosphate method
(38) and selected with G418 (800 
 
m
 
g/ml; Mediatech) for 10 d. 48
clones were selected and 19 analyzed by Northern blot analysis
for the expression of the p65b mRNA. Clone A1B2 that highly
expressed the p65b mRNA was selected for a second round of
cloning and a subclone A1B2.1 was used for further analysis. The
mouse cell lines EL4 T cell, MIC B cell, P815 mastocytoma, and
the macrophage WEHI and RAW 264.7 as well as the rat baso-
philic leukemia (RBL) cell line (American Type Tissue Culture
Collection, Rockville, MD) were maintained in RPMI supple-
mented with 10% fetal bovine serum (FBS), 50 U/ml penicillin,
50 
 
m
 
g/ml streptomycin, 2 mM 
 
l
 
-glutamine and 57 
 
m
 
M 2-mer-
captoethanol at 37
 
8
 
C, and 5% CO
 
2
 
. RAW 264.7 were stimulated
with 100 U/ml of mIFN-
 
g
 
 (R & D Systems, Inc., Minneapolis,
MN) in complete medium for 18 h.
 
Radioligand Binding Assays.
 
Membrane protein was prepared
from p65b transiently transfected CHO cells and mock-trans-
fected CHO cells in buffer A (50 mM Tris, 1 mM EDTA, 1 mM
EGTA, pH 7.4, 1 mM benzamidine, 0.1 mM PMSF, 0.01% bac-
itracin, 0.001% trypsin inhibitor, and 20 
 
m
 
g/ml aprotinin) as pre-
viously described (39). 10 
 
m
 
g of membranes were incubated with
1 nM of [5,6,8,9,11,12,14,15-
 
3
 
H(N)]LTB
 
4
 
 (150–200 Ci/mmol)
or 20 nM [
 
35
 
S]dATP
 
a
 
S (1,250 Ci/mmol; DuPont-NEN) in the
absence or presence of excess cold competitor (1 
 
m
 
M unlabeled
LTB
 
4
 
 or 100 
 
m
 
M 2-methylthio-ATP (2-MeSATP). For satura-
tion binding studies, different concentrations of [
 
3
 
H]LTB
 
4
 
 rang-
ing from 0.1 to 2 nM were incubated with 10 
 
m
 
g membrane pro-
tein in 500 
 
m
 
l of buffer A on ice for 1 h and terminated by rapid
filtration through GF/C glass fiber filters (presoaked in 20 mM
sodium pyrophosphate) on a Millipore vacuum manifold. The fil-
ters were immediately washed five times with 5 ml ice-cold 50
mM Tris-HCl, pH 7.4, dried and bound radioactivity determined
by scintillation counting. Nonspecific binding at each concentra-
tion of [
 
3
 
H]LTB
 
4
 
 was determined by coincubation of samples
 
with an excess (1 mM) of unlabeled LTB4 (Calbiochem-Novabio-
chem, La Jolla, CA). As a control, membrane fractions prepared
from mock-transfected CHO cells were treated identically in par-
allel with transfected cells. For the competitive displacement ex-
periments, increasing concentrations of nonradiolabeled 12(S)-
hydroxy-(5Z, 8Z, 10E, 14Z)-eicosa-tetraenoic acid (12(S)-HETE),
prostaglandin D2 (PGD2) and LTD4 (Sigma Chemical Co., St.
Louis, MO) were incubated with 10 mg membrane protein of
transiently transfected CHO cells in the presence of 1 nM of
[3H]LTB4. Binding curves and Kd and Ki calculations were per-
formed using Prism (GraphPad Software Inc., San Diego, CA).
Calcium Flux. CHO cell clones stably expressing p65b and
untransfected CHO cells in F-12/HAM containing 1% FCS and
purified murine eosinophils in HBSS containing 0.05% BSA were
loaded at 107 cells/ml with 5.0 mM of the acetoxymethyl ester of
fura-2 (fura-2 AM; Molecular Probes, Inc., Eugene, OR) for 60
min at 378C in the dark. Loaded cells were washed twice and re-
suspended in a buffer containing 145 mM NaCl, 4 mM KCl, 1
mM NaHPO4, 0.8 mM MgCl2, 1.8 mM CaCl2, 25 mM Hepes,
and 22 mM glucose. 2 ml of cells (5 3 106 cells/ml) were placed
in a continuously stirring cuvette at 378C in DeltaRAM (Ran-
dom Access Monochromator) fluorimeter (Photon Technology
International, Monmouth Junction, NJ). Changes of cytosolic
free calcium were determined after addition of the agonist by
monitoring the excitation fluorescence intensity emitted at 510
nm in response to sequential excitation at 340 nm and 380 nm.
The data are presented as the relative ratio of fluorescence at 340/
380 nm.
Chemotaxis. 50 ml of purified mouse eosinophils at 2.5 3 106
cells/ml in HBSS and 0.05% BSA were placed in the top of a 48-
well modified Boyden micro-chemotaxis chamber (NeuroProbe,
Cabin John, MD). 30 ml of 10-fold serial dilutions of LTB4 in
HBSS and 0.05% BSA were placed in the bottom wells of the
chamber and were separated from the cells by a 5-mm pore poly-
carbonate filter. The apparatus was incubated at 378C and 5%
CO2 for 60 min and cells that migrated across the filter and ad-
hered to the bottom side of the filter were stained with Diff-Quik
and counted.
Western Blot Analysis. The  peptide MAANTTSPAAPSSP-
GGM(C) corresponding to the NH2-terminal 17 amino acids of
mBLTR plus a COOH-terminal cysteine for coupling was syn-
thesized on an Applied Biosytems Peptide Synthesizer. 2 mg of
this peptide was coupled to 2 mg of ImjectÒ maleimide activated
keyhole limpet hemocyanin (KLH; Pierce Chemical Co., Rock-
ford, IL). The conjugate was purified by size exclusion chroma-
tography on a NAP-1 column (Pharmacia Biotech, Inc.) and used
to immunize two New Zealand white female rabbits. Immune
serum from both rabbits was pooled and affinity purified on a
SulfolinkÒ gel (Pierce Chemical Co.) to which the peptide had
been coupled via its COOH-terminal cysteine residue to a 12-
atom spacer arm attached to the gel. Purified murine eosinophils
from IL-5 transgenic mice or purified human eosinophils were
washed twice in cold PBS, and lysed in 10 mM Tris, pH 7.4, 150
mM NaCl, 1 mM EDTA, 1 mM EGTA, NP-40 1%, and Triton
X-100 1% supplemented with antiproteases (10 mg/ml leupep-
tin, 1 mg/ml pepstatin A, and 4 mg/ml aprotinin). Murine alveo-
lar macrophages (mMAC) were obtained by bronchoalveolar lav-
ages (BAL; 5 ml PBS and 0.6 mM EDTA) of normal male
BALB/c mice and were lysed in the same lysis buffer. Cell lysates
were boiled in sample buffer (250 mM Tris-HCl, pH 6.8, 20%
glycerol, and 2% 2-mercaptoethanol) for 5 min. Protein extracts
were loaded onto a 10% SDS-PAGE gel and electrophoretically
separated. Proteins were transferred onto nitrocellulose membrane1066 Murine Leukotriene B4 Receptor
(Hybond ECL; Amersham Pharmacia Biotechnology Inc., Piscat-
away, NJ) and blocked overnight at 4°C in TBS, pH 7.6, con-
taining 0.1% Tween-20 (TBST) and 5% nonfat dry milk (blotto).
The membrane was sequentially incubated for 1 h at room tem-
perature with the affinity-purified rabbit anti-BLTR (1 mg/ml) in
blotto and then with a HPR-conjugated goat anti–rabbit (Kirke-
gaard & Perry Laboratories, Inc., Gaithersburg, MD) diluted to
1:5,000 in blotto. The membrane was washed repeatedly in TBST
between incubations. Blots were developed using ECL kit from
Amersham. Controls were performed using preimmune rabbit se-
rum at 1/20,000 (z0.5 mg/ml) and by preincubating 5 mg of the
rabbit anti-BLTR antibody with 100 mg of the immunizing pep-
tide in a volume of 110 ml PBS (z1,500-fold molar excess of
peptide) for 1 h at room temperature before dilution into 10 ml
of blotto for the Western blot analysis.
Aspergillus fumigatus Model of Allergic Pulmonary Inflammation.
A mixture of culture filtrate and mycelial extracts of Aspergillus fu-
migatus (Af ) was provided by Bayer Pharmaceuticals (Spokane,
WA) and was diluted to a concentration of 2 mg/ml with normal
saline. Mice were anesthetized by Metofane inhalation (methoxy-
fluorane; Pittman-Moore, Mundelein, IL), and 100 mg (50 ml) of
Af antigen or 50 ml of normal saline was applied to the left nostril
using a micropipette with the mouse held in the supine position.
After instillation, mice were held upright until alert. Mice were
immunized three times a week for 3 wk. 12 h after the final sen-
sitizing dose animals were killed. RNA was prepared from lung
tissue using a modified version of guanidium isothiocyanate
method. In brief, 4 M guanidium isothiocyanate, 25 mM sodium
citrate, pH 7.0, 0.5% sarcosyl, and 0.1 M b-mercaptoethanol was
used to solubilize lung tissue (10 ml/lung). Phenol/chloroform
(1:1) and sodium acetate, pH 4.8, were added and the mixture
was passed through a 23-G needle three times. Tubes were spun
at 10,000 g for 20 min and RNA was precipitated from aqueous
phase with equal volume of isopropanol for 1 h at 2208C. RNA
was suspended in the extraction solution and again precipitated
with isopropanol. Pellets were washed twice with 75% ethanol,
resuspended in dH20, and heated to 658 for 10 min. 5 mg of
RNA/lane was run on a low-formaldehyde/1% agarose gel, cap-
illary blotted onto GeneScreen Plus (Dupont-NEN).
Results
Molecular Cloning of a Novel mSTR. Degenerate primers
were designed based on the sequences of the conserved
transmembrane domains II, III, and VII of chemoattractant
receptors for FMLP, C5a, PAF, Lipoxin A4, and the
chemokine receptors CXCR1, CXCR2, CXCR4, and
CCR1. RT-PCR using degenerate primers to transmem-
brane domains II and III and mRNA isolated from murine
eosinophils amplified an z200-bp product, a size consistent
with the known distance between these transmembrane
domains. Sequence analysis of this PCR product identified
a novel open reading frame with z30% homology to other
chemoattractant receptors reported at the time. Therefore,
this PCR product was used to screen a murine eosinophil
cDNA library. 92 out of z106 independent recombinant
plaques hybridized strongly with this PCR product and 20
were randomly selected for further analysis. Restriction di-
gestion, Southern blot, and sequence analyses revealed that
these clones were from the same gene but contained differ-
ent 59 ends. Clone p65b represented a class of clones that
contained an open reading frame beginning with methionine
and contained the most 59 sequences and was selected for
further analysis.
Analysis of the p65b cDNA. To determine the cap site
of this gene, 59 RACE was performed using eosinophil
mRNA and a nested set of internal primers. This analysis
revealed 20 additional bases 59 of the cDNA p65b (Fig. 1 A,
underlined). This makes the mature p65b cDNA 1,406 bp in
length with a 1,053-bp open reading frame, a 137-bp 59-
untranslated region, and a 198-bp 39-untranslated region
that contains the polyadenylation signal ATTAAA (Fig. 1
A, double underlined). The open reading frame encodes a
polypeptide of 351 amino acids with an estimated molecu-
lar mass of 38 kD (Fig. 1 A). The primary structure of the
p65b open reading frame was 78% identical to a human
gene independently entered in the data base as an orphan
STR (CMKRL1 [40] and R2 [41]) as a novel purinoceptor
(P2Y7; reference 29) and as a receptor for LTB4 called
BLTR (30; Fig. 1 B). The amino acid sequence of the
p65b open reading frame was also related to other G pro-
tein–coupled chemoattractant receptors sharing 32% iden-
tity with the murine C5a receptor (mC5aR), 32% identity
with the murine IL-8 receptor (mCXCR2), 30% identity
to mFMLPR, 29% identity with the murine lipoxin A4 re-
ceptor (mLXAR), and 26% identity with the murine plate-
let-activating factor receptor (mPAFR). Using the p65
cDNA as a probe we screened a human lung library under
reduced stringency and isolated six clones that were all
identical to this human gene CMLKR/R2/P2Y7 /BLTR.
The fact that we isolated only this gene that is 79 and 78%
identical in nucleic acid and amino acid sequence, respec-
tively, to p65b, strongly suggests that p65b is the mouse
orthologue of this human gene. Based on this and the func-
tional data presented below we have named p65b mBLTR.
The mBLTR open reading frame exhibits several se-
quence motifs that are characteristic of G protein–coupled
receptors, including seven hydrophobic transmembrane
domains, conserved prolines in several of the transmem-
brane domains, and conserved cysteines in extracellular do-
mains II and III for intramolecular chain disulfide bonding
(23). In addition, similar to other chemoattractant recep-
tors, mBLTR has two potential N-linked glycosylation
sites (Fig. 1 A, bold), one in the extracellular NH2-terminal
segment and the other in the third extracellular domain.
The receptor also contains a serine and threonine-rich
COOH-terminal intracytoplasmic segment. Analogous re-
gions of other STRs are sites of phosphorylation involved
with receptor desensitization and internalization (23).
When comparing the amino acid sequence of the mouse
and human BLTR, it is striking that the three intracyto-
plasmic loops are identical across species, while not being
conserved across the subfamily of chemoattractant receptors
(Fig. 1 B). This suggests that the BLTRs may be coupled to
a unique, well-conserved, signaling pathway among the
chemoattractant receptors.
In Vitro Translation. To determine if the p65b cDNA
encoded a complete open reading frame, in vitro transcrip-
tion and translation were performed (Fig. 2). This was rel-1067 Huang et al.
evant because the open reading frame for the human gene
reported by one group (41) was 25 amino acids upstream of
the one we have proposed for the murine cDNA. In addi-
tion, the murine cDNA contains no in frame stop codons
59 of the proposed initiating methionine. A linearized p65b
plasmid was used as a template to synthesize sense (T3) and
antisense (T7) cRNA. In vitro translation using a rabbit
reticulocyte lysate revealed that the sense cRNA encoded a
protein that migrated as an z31-kD species on SDS-
PAGE. As controls, the translation of antisense cRNA (T3)
and no input cRNA (B) did not produce a protein prod-
uct. To determine if this protein is glycosylated, in vitro
translation was performed in the presence of dog pancreatic
microsomes (Fig. 2). This revealed an upward shift in mo-
bility on SDS-PAGE of z4 kD, indicating that the
mBLTR protein is N-linked glycosylated and z35 kD.
This experiment also told us that the p65b cDNA con-
tained a translatable message. In fact, the upstream me-
thionine proposed by this one group (41) is likely the result
of using PCR on genomic DNA because the two other re-
ports identifying this human gene as a cDNA (29, 40) re-
vealed an initiating methionine in a similar position to the
one that we found for the murine gene.
Functional Characterization, Specific Binding to LTB4. Since
the proposed human orthologue of this gene has been
shown to be both a receptor for LTB4 (30) and dATP (29), we
performed radioligand binding experiments using [3H]LTB4
and [35S]dATP on CHO cells transiently transfected with
the mBLTR cDNA p65b. Membrane fractions of transiently
transfected and mock-transfected CHO cells were prepared
and incubated with 1 nM [3H]LTB4 and 20 nM [35S]dATP
(Fig. 3, A and B). To determine nonspecific binding,
membrane fractions were also incubated with [3H]LTB4 in
the presence of excess (1 mM) nonradiolabeled LTB4 and
[35S]ATP in the presence of excess (100 mM) nonradio-
labeled 2-MeSATP. Transfected cells specifically bound
Figure 1. Nucleotide and amino acid sequence of mBLTR cDNA. (A)
Nucleotide sequence is numbered on the left and the deduced amino acid
sequence is numbered beginning with the predicated initiating methio-
nine on the right. 20 nucleotides obtained from 59 RACE are underlined
and the polyadenylation signal sequence is double underlined. Two puta-
tive N-linked glycosylation sites are indicated in bold. These data
are  available from GenBank/EMBL/DDBJ under accession number
AF044030. (B) Amino acid sequence alignment of the mBLTR open
reading frame with the chemoattractant receptors: human LTB4 receptor
(hBLTR), murine lipoxin A4 receptor (mLXAR), murine formyl-Met-
Leu-Phe receptor (mFMLPR), murine C5a receptor (mC5aR), and mu-
rine CXCR2. The transmembrane domains predicted from a Kyte-
Doolittle hydrophobicity analysis are overlined and labeled as I-VII. The
shaded area indicates $90% sequence homology and the boxed area indi-
cates regions of identity.
Figure 2. In vitro transcrip-
tion and translation of the
mBLTR cDNA (p65b). Transla-
tion in the presence (1) or ab-
sence (2) of pancreatic microso-
mal membranes of p65b cRNA
transcribed with T3 polymerase
(sense) and T7 polymerase (anti-
sense control). B (blank) transla-
tion in the absence of added
cRNA. Molecular mass markers
in kD are indicated on the left.1068 Murine Leukotriene B4 Receptor
[3H]LTB4, whereas nontransfected cells did not (n 5 4 sep-
arate transfections; Fig. 3 A). In contrast, there was no de-
tectable specific binding of [35S]dATP to either mock
transfected or mBLTR (p65b)-transfected CHO cells (Fig.
3 B). Saturation binding analysis and Scatchard analysis re-
vealed a single class of specific high affinity binding sites for
[3H]LTB4 with a dissociation constant (Kd) of 0.64 6 0.14
nM (mean 6 SE of four independent measurements
performed in duplicate; Fig. 3 C). To test the specificity
of this interaction, we examined the competitive displace-
ment of [3H]LTB4 by different eicosanoids in the arachi-
donic acid metabolic pathway on membrane fractions of
mBLTR (p65b)-transfected CHO cells. LTB4 competed
the binding of 1 nM [3H]LTB4 with a Ki of 2.1 nM,
whereas the structurally related compound 12(S)-HETE
competed [3H]LTB4 binding with a Ki of 34 nM (Fig. 3 D).
LTD4, LTE4, and PGD2 did not significantly compete for
[3H]LTB4 binding to the transfected cell membranes (Fig. 3
D). Thus, these data suggest that LTB4 is a specific high af-
finity ligand for this receptor and hence the proposed des-
ignation as murine BLTR.
Functional Characterization, LTB4-induced Calcium Flux.
Signaling through G protein–coupled seven transmem-
brane spanning chemoattractant receptors typically gener-
ates a transient rise in intracellular calcium. We have gener-
ated stable CHO cell clones that express the mBLTR
cDNA p65b and investigated the ability of LTB4 to induce
a calcium flux in these cells. As shown in Fig. 4, LTB4 at
concentrations ranging from 10 nM to 20 mM induced a
rapid calcium flux in fura-2 loaded mBLTR-CHO cells,
but not the parental (wild-type) CHO cells. This response
was dose dependent with increasing concentrations of
LTB4 inducing a greater increase intracellular calcium.
These results indicate that LTB4 induces a calcium flux in
CHO cells through the cell surface receptor mBLTR. Sur-
prisingly, we did not observe desensitization in these CHO
transfectants at concentrations ranging from 10 nM to 20
mM (Fig. 4).
mBLTR mRNA Expression. Northern blot analysis of
mRNA from various mouse tissues revealed that the ma-
ture mBLTR transcript migrates as a 1.45-kb mRNA and
is quite restricted in its expression pattern (Fig. 5). Low levels
of constitutive expression were detected only in the lung,
lymph nodes, and spleen. No expression was seen in the
thymus, kidney, liver, brain, heart, or testis. Purified eosin-
ophils from IL-5 transgenic mice expressed high levels of
mBLTR mRNA constitutively, while bone marrow–derived
macrophages, bone marrow–derived mast cells (data not
shown), and various mouse cell lines, including the EL4 T
cell line, MIC B cell line, P815 mastocytoma line, and the
rat RBL basophilic leukemia line did not (Fig. 5 B). The
WEHI macrophage line constitutively expressed low levels
of mBLTR mRNA and IFN-g induced its expression in
the RAW 264.7 macrophage cell line (Fig. 5 B). Resting
peritoneal cells did not express detectable mBLTR mRNA;
however, its expression was dramatically induced in both
activated macrophages and neutrophils elicited into the
peritoneum (Fig. 5 C). Furthermore, mBLTR was highly
expressed in T cell lymphomas (Fig. 5 D) that spontaneously
arose in c-myc transgenic mice homozygous for p53 null
alleles (35), suggesting that T cells can express BLTR. The
single RNA species seen above 1.45 kb (Fig. 5, B and C) al-
Figure 3. Binding of [3H]LTB4
to mBLTR transfected CHO cell
membranes. (A) 1 nM [3H]LTB4
and (B) 20 nM [35S]dATP bind-
ing to membranes (10 mg) of
mBLTR (p65b) transiently trans-
fected CHO cells or mock trans-
fected CHO cells in the absence
(Total Binding) and presence
(Nonspecific Binding) of unlabeled
excess ligand (mean 6 SE, n 5
4). (C) Binding isotherm and
Scatchard analysis of [3H]LTB4
binding to membrane of mBLTR
(p65b) transfected CHO cells
(mean, n 5 4). (D) Inhibition of
[3H]LTB4 binding to membrane
fractions of mBLTR-transfected
CHO cells by various eicosanoids,
including 12(S) HETE, LTD4,
LTE4,  and PGD2.1069 Huang et al.
most certainly represents the primary unspliced BLTR
transcript. The multiple RNA species seen below 1.45 kb
in the eosinophil lane in Fig. 5 B are degraded BLTR tran-
scripts. These lower bands were not seen in poly(A)1 eosin-
ophil RNA (Fig. 5 E). Thus, mBLTR mRNA is predomi-
nantly expressed in activated leukocytes, including IL-5
exposed eosinophils, elicited peritoneal neutrophils and
macrophages, and IFN-g–simulated macrophages.
BLTR Protein Expression on Eosinophils and Alveolar Mac-
rophages. To study the expression of the mBLTR protein,
we have generated an affinity-purified rabbit antibody di-
rected against the NH2-terminal 17 amino acids of the pre-
dicted open reading frame. This was done by immunizing
rabbits with the peptide coupled to KLH and then purify-
ing the immune serum from two rabbits by peptide affinity
chromatography. Western blot analysis using this affinity-
purified antibody on total cell lysates of eosinophils purified
from IL-5 transgenic mice and alveolar macrophages isolated
by bronchoalveolar lavage (BAL) from wild-type mice re-
vealed an z32.5-kD species in both murine eosinophils and
macrophages (Fig. 6). Interestingly, lower levels of a comigrat-
ing band were also seen in human eosinophils purified from a
nonatopic donor (Fig. 6). This antibody reaction was specific
for the immune serum and was not seen with the preimmune
serum (Fig. 6). In addition, the BLTR immunoreactivity seen
with the immune serum was completely blocked by an excess
of the mBLTR immunizing peptide (Fig. 6).
mBLTR Expression in a Murine Model of Allergic Pulmonary
Inflammation. To assess the expression of mBLTR mRNA
in the setting of allergic inflammation, we subjected mice
to inhalation of the mold allergen Aspergillus fumigatus (Af).
We have previously reported that repeated intranasal instil-
lation of Af gives rise to an intense eosinophil-predominant
inflammatory infiltrate (42). BAL eosinophil counts are ele-
vated by two to three orders of magnitude in Af-treated
mice (105–106 eosinophils/ml) compared with controls (mean
103 eosinophils/ml) and the lungs of mice treated with Af
have dense inflammatory infiltrates. The infiltrate contains
predominantly eosinophils with a significant number of ad-
mixed lymphocytes and occasional histiocyte-like cells in
peribronchial and perivascular cuffs (see cover of this issue).
In the setting of repeated allergen inhalation, Af-treated
mice develop a baseline level of eosinophils in their BAL
and lung biopsies. Superimposed on this background in-
flammation is a new influx of eosinophils elicited by each
successive Af dose. We have found that waves of infiltrat-
ing eosinophils in the BAL and tissue peak 12 h after each
Af exposure (Oettgen, H.C., personal observation). As can
be seen in Fig. 7, levels of mBLTR are elevated (approxi-
mately threefold) in the lungs of mice after repeated allergen
inhalation (compare time 0 in the saline- and Af-treated
mice). In addition, after inhalation of Af in sensitized mice,
mBLTR is further upregulated, peaking at z8 h (approxi-
mately fivefold over saline treated), consistent with the re-
ceptor being expressed on influxing eosinophils.
Murine Eosinophils Respond to LTB4. Since the mBLTR
mRNA and protein was highly expressed in murine eosin-
ophils isolated from IL-5 transgenic mice, and its mRNA
was upregulated in the lungs of mice in a murine model of
allergic pulmonary inflammation in a time course consis-
tent with eosinophil tissue recruitment, we sought to de-
termine if mBLTR was a functional chemotactic receptor
on eosinophils. To do this, we examined the chemotactic
and calcium flux responses of mouse eosinophils to differ-
ent concentrations of LTB4. Eosinophils showed a dose-
dependent bell-shaped chemotactic response to LTB4 with
an optimum concentration of 1–10 nM (Fig. 8 A). LTB4
also triggered a robust calcium flux in murine eosinophils
loaded with fura-2 (Fig. 8 B). In addition, 100 nM LTB4
almost completely desensitized eosinophils to a subsequent
100 nM LTB4 challenge (Fig. 8 B). However, the eosino-
phils were still able to respond to PAF and human eotaxin-2
indicating that PAF, eotaxin-2, and LTB4 use distinctive
receptors on the membranes of eosinophils for signal trans-
duction. Of note, although 100 nM LTB4 induced homol-
ogous desensitization in eosinophils (Fig. 8 B), this was not
Figure 4. LTB4-induced calcium flux in
mBLTR-CHO transfectants. Fura-2 loaded stable
mBLTR-CHO clone (A1B2.1) and the parental
wild-type CHO cells (Wt-CHO) were stimulated
with LTB4 (concentrations indicated on the right) at
the times indicated by the arrows. [Ca21]i levels
were measured as ratio fluorescence of excitation at
340/380 nm over time.1070 Murine Leukotriene B4 Receptor
the case for the mBLTR-CHO transfectants (Fig. 4). Al-
though the binding affinity of LTB4 for BLTR is very sim-
ilar in CHO transfectants and leukocytes, BLTR-mediated
signaling appears to have significant differences in CHO
cells and eosinophils.
Discussion
In an effort to identify novel chemoattractant receptors,
we performed degenerate PCR based on the sequences of
known chemoattractant receptors on cDNA isolated from
murine eosinophils and isolated a gene that is 78% identical
to a human gene that has been reported to be a purinocep-
tor (P2Y7; reference 29) and an LTB4 receptor (BLTR; ref-
erence 30). We have shown that this murine gene is a
functional LTB4 receptor and propose the name mBLTR.
Interestingly, mBLTR was highly expressed on murine
eosinophils isolated from IL-5 transgenic mice and was up-
regulated in the lungs of mice after the induction of eosin-
ophilic pulmonary inflammation.
Leukotrienes constitute a class of potent biological medi-
ators of inflammation that have been implicated in a wide
variety of human inflammatory disease, including asthma
and allergic rhinitis, cystic fibrosis, inflammatory bowel dis-
ease, psoriasis, acute respiratory distress syndrome, multiple
sclerosis, and rheumatoid arthritis (43–45). Their biosyn-
thesis derives from 5-lipoxygenese-catalyzed oxygenation
of arachidonic acid in cells of the myeloid lineage. LTB4 is
primarily active on leukocytes causing chemotaxis, adhe-
sion, and activation, whereas the cysteinyl leukotrienes
(LTC4, LTD4, and LTE4) are primarily active on smooth
muscle, causing bronchoconstriction, capillary leak, and
mucus production.
Although the leukotrienes are known to exert their bio-
logical actions through stereoselective membrane receptors
(31), structural information has been lacking. Radioligand
binding studies have identified an LTB4 receptor on leuko-
cytes that has been given the designation BLTR (31). LTB4
can also bind and activate the intranuclear transcription fac-
tor peroxisome proliferator-activated receptor (PPAR)a,
resulting in the activation of genes that terminate inflam-
matory processes (46). BLTR has been characterized as a
binding site for [3H]LTB4 on human neutrophils with a Kd
of 10 (47), 0.46 (48), and 1.5 nM (49) and on guinea pig
eosinophils with a Kd of 1.4 nM (16). Recently, a human
BLTR has been molecularly identified as G protein–cou-
pled STR (30). Membrane fractions of COS-7 cells trans-
Figure 5. Expression of the mBLTR mRNA. (A) Northern blot anal-
ysis of 1.5 mg poly(A)1 RNA isolated from the indicated organs of a
healthy FVB mouse. (B) Northern blot analysis of 10 mg total RNA iso-
lated from the EL4 T cell line, MIC B cell line, P815 mastocytoma line,
RBL basophilic line, WEHI macrophage line, RAW 264.7 macrophage
cell line untreated or treated for 18 h with 200 U/ml IFN-g, J774 mac-
rophage line, bone marrow derived macrophages (MØ), and eosinophils
purified from IL-5 transgenic mice. (C) Northern blot analysis of 10 mg
total RNA isolated from leukocytes recovered from peritoneal lavage be-
fore (R, resting) or after (elicited) intraperitoneal casein injection and per-
coll density gradient purification. M, macrophage fraction (76% macrophages,
and 24% neutrophils); N, neutrophil fraction (95% neutrophils, 5% mac-
rophages). (D) Northern blot analysis of 1.5 mg poly(A)1 RNA isolated
from Thy1 positive fresh lymphomas obtained from lymph nodes (L.N.)
or thymus (Thy). Each lane contains RNA isolated from a lymphoma that
spontaneously arose in a different bigenic mouse containing a c-myc
transgene and p53 null alleles numbered and described in Elson et al. (35).
(E) Northern blot analysis of 2 mg of poly(A)1 RNA and 10 mg of total
RNA before poly A selection (T) isolated from eosinophils purified from
IL-5 transgenic mice. Blots were sequentially probed with the mBLTR
(p65b) cDNA (top of each panel) and rpL32 or 28s as a control for RNA
loading (bottom of panel).
Figure 6. Expression of the
mBLTR protein. Protein ex-
tracts of eosinophils obtained
from two IL-5 transgenic mice
(30  mg/lane), murine alveolar
macrophages (20 mg/lane), and
human eosinophils purified
from a normal donor (30 mg/
lane), were loaded onto a 10%
SDS-PAGE gel and electro-
phoretically separated. Western
blot analysis was performed using
an affinity-purified rabbit anti–
mouse BLTR antibody. The po-
sition of BLTR protein is indi-
cated by the arrow and molecular mass markers in kD are indicated to the
left of the top blot. The affinity-purified antibody cross-reacts with the
human receptor. This antibody reaction was specific for the immune se-
rum and was not seen with the preimmune serum and was completely
blocked by excess BLTR peptide (bottom two blots). The exposure times
are indicated below the top blots and to the left of the bottom blots. EOS,
eosinophils; MAC, alveolar macrophages; Hu, human.1071 Huang et al.
fected with human BLTR were shown to bind LTB4 with
a Kd of human 0.154 (30) or 2.1 nM (50). In CHO cells
stably expressing this receptor, LTB4 induced a calcium flux,
D-myo-inositol-1,4,5-triphosphate (IP3) accumulation, in-
hibition of adenylate cyclase, and chemotaxis (30). How-
ever, this same human receptor was also cloned from a
human erythroleukemia cell cDNA library using a chicken
P2Y3 cDNA probe, and when it was transfected into COS-7
cells, it resulted in a binding site for dATP and ATP with a
Kd of 7.3 and 37 nM, respectively (29).
We have isolated a mouse gene that is highly related in
sequence to the human gene described above. CHO cells
transfected with this murine gene, but not mock-trans-
fected CHO cells, specifically bound LTB4 with a Kd of 0.6 6
0.1 nM. Furthermore, LTB4 induced a dose-dependent in-
tracellular calcium flux in CHO stable transfectants, but not
control CHO cells. In contrast, dATP did not specifically
bind to these CHO transfectants or CHO cells expressing
the human gene (30). However, like Yokomizo et al. (30),
we did find that dATP specifically bound to untransfected
COS-7 cells (data not shown). In fact, COS-7 were shown
to contain an endogenous P2Y2 receptor (51). In addition,
a range of nucleotides, including ATP, UTP, ADP, UDP,
and dATP, had no effect on phospholipase C or adenyl cy-
clase activities in 1321N1 human astrocytoma cells express-
ing an epitope-tagged human BLTR gene (51). These data,
together with the low sequence homology of this gene
with other P2Y receptors, suggest that the gene we have
isolated is a murine LTB4 receptor.
LTB4 was discovered based on its potent chemotactic ac-
tivity on neutrophils (52) and we have seen high levels of
BLTR expression in elicited neutrophils. However, we
have also detected the expression of BLTR on other leuko-
cytes where the biological activities of LTB4 are less clear.
For example, we have seen BLTR expression in elicited
peritoneal macrophages, alveolar macrophages, and IFN-
g–stimulated RAW 264.7 macrophages. Although acti-
vated macrophages are a major source of LTB4, BLTR has
not been described on monocytes or macrophages. How-
ever, LTB4 has been shown to augment IL-6 production
by human monocytes (53) and enhance the ability of peri-
toneal macrophages to phagocytose and kill Salmonella typh-
imurium and Pseudomonas aeruginosa (54). In addition, mice
deficient in 5-lipoxygenase were more susceptible to Kleb-
siella pneumonia in association with decreased alveolar
macrophage phagocytic and bactericidal activities (55).
These defects in macrophage function were overcome by
the addition of exogenous LTB4, suggesting a functional
role for LTB4 in alveolar macrophage host defense (55). We
have also detected constitutive expression of BLTR in
lymph nodes, and high levels of BLTR expression were
seen in T cell lymphomas, suggesting that BLTR can be
expressed on T lymphocytes. Although LTB4 receptors
have not been described on lymphocytes, LTB4 has been
shown to induce IL-2 and IFN-g production from T cells
and to augment NK cell cytotoxicity and sensitivity to IL-2
by upregulating IL-2 receptor expression (56–58). The
cloning of BLTR will allow new studies aimed at under-
standing the role of LTB4 and BLTR in lymphocyte and
macrophage biology.
mBLTR was highly expressed in murine eosinophils iso-
lated from IL-5 transgenic mice. Consistent with this,
LTB4 was a potent chemoattractant for murine eosinophils,
inducing peak chemotaxis at 1–10 nM and inducing a ro-
bust calcium flux at 100 nM. LTB4 has been shown to in-
duce guinea pig eosinophil superoxide anion generation
and chemotaxis in vitro and in vivo (16, 17, 59). In addi-
tion, eosinophils purified from IL-5 transgenic mice, la-
beled with 111In and injected intravenously into wild-type
mice were recruited into the skin by LTB4 (60). In con-
trast, human eosinophils have been reported to respond
poorly to LTB4 when compared with PAF (14, 15, 17).
Our results indicate that murine eosinophils from IL-5 trans-
genic mice respond robustly to LTB4 in manner comparable
with PAF. In addition, Western blot analysis revealed high
levels of mBLTR protein in these IL-5–exposed murine
eosinophils and lower levels of BLTR in human eosino-
phils isolated from the peripheral blood of a nonatopic do-
nor. It may be that priming with cytokines, such as IL-5, is
important for regulating the expression or responsiveness of
BLTR on human eosinophils (61).
Specific antagonists of LTB4 have revealed a role of
LTB4 in regulating the recruitment of eosinophils into tis-
sues in vivo. In a guinea pig model of antigen-induced pul-
Figure 7. Expression of
mBLTR in lungs of mice in the
Af model of allergic pulmonary
inflammation. Mice were treated
three times a week for a period
of three weeks with 50 mg Af in-
tranasally (or normal saline in
“sham” animals). (A) Northern
blot analysis of 5 mg of total
RNA isolated from the lungs of
mice at the indicated times after
the last Af treatment or saline
treatment (sham control). Each
lane represents a different mouse.
The blot was probed sequentially with the mBLTR cDNA and rpL32 as a control for RNA loading. (B) Quantitation of the Northern blot using a Phos-
phorImager expressed as the percentage of rpL32 signal for each lane (PhosphorImager signal of BLTR/rpL32 3 100).1072 Murine Leukotriene B4 Receptor
monary inflammation, pretreatment of sensitized guinea
pigs with a selective LTB4 antagonist before antigen provo-
cation decreased the influx of eosinophils into the lung and
BAL fluid but had no effect on the influx of neutrophils
(62). Likewise, in a murine model of experimental allergic
encephalomyelitis, pretreatment of mice with a selective
LTB4 receptor antagonist markedly blocked the recruitment
of eosinophils into the spinal cord and completely inhibited
the development of paralysis (63). The influx of lympho-
cytes was unaffected by pretreatment with the LTB4 recep-
tor antagonist, thus revealing an unrecognized role for eo-
sinophils in the pathogenesis of this disease. Furthermore,
the specific inhibition of 5-lipoxygenase with zileuton re-
duced eosinophil influx into the lung tissue and BAL fluid
in a murine model of allergic pulmonary inflammation and
also prevented airway mucus release in these mice (64).
Studies in humans have also implicated leukotrienes in the
pathogenesis of allergic airway inflammation. Increased lev-
els of LTB4 and LTC4 were recovered in the BAL fluid af-
ter endobronchial antigen challenge compared with pre-
challenge levels (65, 66). Nocturnal levels of LTB4 and
cysteinyl leukotrienes were elevated in the BAL fluid of pa-
tients with nocturnal asthma compared with normal con-
trols (67). In these asthmatic subjects, zileuton decreased
BAL fluid LTB4 levels, blood eosinophil levels, and im-
proved FEV1 (67). In fact, zileuton is now widely used
clinically in the treatment of human asthma (68–70).
Our results clearly demonstrate that LTB4 can be a po-
tent agonist for murine eosinophils and that these cells can
express high levels of BLTR. Furthermore, we have seen
that levels of BLTR mRNA in the lungs of mice are in-
creased after the induction of eosinophilic pulmonary in-
flammation in a time course consistent with the influx of
eosinophils. Taken together with the above mentioned in
vivo studies using specific LTB4 antagonists, these data sug-
gest that LTB4 and BLTR play an important role in the re-
cruitment of eosinophils into tissues. In addition, we have
also found that BLTR is expressed in other leukocytes, in-
cluding alveolar macrophages, IFN-g stimulated macrophages,
elicited peritoneal macrophages and neutrophils, and T cell
lymphomas, suggesting a broad role for LTB4 in host de-
fense and inflammation.
In conclusion, while searching for novel chemoattractant
receptor genes expressed in murine eosinophils, we have
isolated a gene that encodes a functional cell surface recep-
tor for LTB4, mBLTR. The identification of the mBLTR
gene will help elucidate the role of the LTB4 pathway in
controlling the movement and activation of leukocytes in
models of human disease.
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Figure 8. LTB4-induced chemotaxis and calcium flux of mouse eosin-
ophils. (A) Chemotaxis of murine eosinophils in response to the indicated
concentrations of LTB4 (mean 6 SE, n 5 three separate experiments). (B)
Calcium flux responses of murine eosinophils. Each tracing represents the
[Ca21]i levels of fura-2-loaded eosinophils measured as relative fluores-
cence over time. Arrows mark the time of addition of the indicated ago-
nist LTB4 (100 nM), PAF (5 mM), and human eotaxin-2 (1.6 mM).1073 Huang et al.
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